A shared genetic signature for common chronic pain

conditions and its impact on biopsychosocial traits

Scott F. Farrell^{a,b,c}, Pik-Fang Kho^{d,e,f}, Mischa Lundberg^{g,h}, Adrián I. Campos^{i,j}, Miguel E. Rentería^j, Rutger M. J. de Zoete^k, Michele Sterling^{a,b}, Trung Thanh Ngo^{a,g†} & Gabriel Cuéllar-Partida^{g†*}

Author affiliations:

^a RECOVER Injury Research Centre, The University of Queensland, Herston QLD, Australia

^b NHMRC Centre of Research Excellence: Better Health Outcomes for Compensable Injury, The University of Queensland, Herston QLD, Australia

^c Tess Cramond Pain & Research Centre, Royal Brisbane & Women's Hospital; Surgical,

Treatment & Rehabilitation Service (STARS), Herston QLD, Australia

^d Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford CA, USA

^e Molecular Cancer Epidemiology Laboratory, Department of Genetics & Computational

Biology, QIMR Berghofer Medical Research Institute, Herston QLD, Australia

^f School of Biomedical Sciences, Queensland University of Technology, Brisbane QLD,

Australia

⁹ Diamantina Institute, The University of Queensland & Translational Research Institute, Woolloongabba QLD, Australia

^h Transformational Bioinformatics, CSIRO Health & Biosecurity, North Ryde NSW, Australia

ⁱ Institute for Molecular Bioscience, The University of Queensland, St Lucia QLD, Australia

^j Genetic Epidemiology Laboratory, Department of Genetics & Computational Biology,

QIMR Berghofer Medical Research Institute, Herston QLD, Australia

^k School of Allied Health Science & Practice, The University of Adelaide, Adelaide SA,

Australia

[†] These authors contributed equally to this work

^{*} Current address: 23andMe Inc., Sunnyvale CA, United States of America

Correspondence to:

Dr Scott Farrell

RECOVER Injury Research Centre — Surgical, Treatment & Rehabilitation Service

(STARS | Level 7), 296 Herston Rd, Herston QLD 4029, Australia.

E: Scott.Farrell@uq.edu.au | P: +61 7 334 64791 | F: +61 7 334 69136

Dr Trung Ngo

RECOVER Injury Research Centre — Surgical, Treatment & Rehabilitation Service

(STARS | Level 7), 296 Herston Rd, Herston QLD 4029, Australia.

E: Trung.Ngo@uq.edu.au | P: +61 42 111 7258

Running Title: Biopsychosocial genetic signature of chronic pain

Disclosures: AIC was supported by a UQ Research Training Scholarship from The University of Queensland. PFK was supported by an Australian Government Research Training Program Scholarship from Queensland University of Technology (QUT). RECOVER Injury Research Centre (MS, SFF) receives unrestricted grant funding from the Motor Accident Insurance Commission (Queensland). The funders had no role in the design or interpretation of this study. This research was initially carried out at the Translational Research Institute (TRI), Woolloongabba, QLD 4102, Australia. TRI is supported by a grant from the Australian Government. SFF, TTN & GC-P conceived the study. TTN & GC-P co-supervised the study. SFF & TTN performed the literature search. AIC & MER performed the GWAS. SFF & ML performed downstream analyses with support from GC-P. SFF prepared the figures with support from TTN & GC-P. All authors contributed to interpretation of results. SFF, TTN & GC-P wrote the manuscript with feedback from all coauthors. GC-P contributed to this study while employed at The University of Queensland. He is now an employee of 23andMe, Inc and may hold stock in the company. The other authors have no conflicts of interest to declare.

Abstract

The multifactorial nature of chronic pain with its numerous comorbidities presents a formidable challenge in disentangling their aetiology. Here, we performed genome-wide association studies of eight regional chronic pain types using UK Biobank data (N=4,037-79,089 cases; N=239,125 controls), followed by bivariate linkage disequilibrium-score regression and latent causal variable analyses to determine (respectively) their genetic correlations and genetic causal proportion (GCP) parameters with 1,492 other complex traits. We report evidence of a shared genetic signature across common chronic pain types as their genetic correlations and GCP parameter directions were broadly consistent across a wide array of biopsychosocial traits. Across 5,942 significant genetic correlations, 570 trait pairs could be explained by a causal association (|GCP| > 0.6; 5% false discovery rate), including 82 traits affected by pain while 488 contributed to an increased risk of chronic pain such as certain somatic pathologies (e.g., musculoskeletal), psychiatric traits (e.g., depression), socioeconomic factors (e.g., occupation) and medical comorbidities (e.g., cardiovascular disease). This data-driven study has demonstrated a novel & efficient strategy for identifying genetically supported risk & protective traits to enhance the design of interventional trials targeting underlying causal factors and help accelerate the development of more effective treatments with broader clinical utility.

Key words: Chronic Pain; Musculoskeletal Pain; Genome-Wide Association Studies; Genetic Predisposition to Disease; Precision Medicine

Introduction

Despite enormous research efforts into determining the aetiology of chronic pain, common musculoskeletal conditions such as back pain and neck pain remain a major clinical and scientific challenge.¹ Over the past decade however, large-scale genome-wide association studies (GWAS) have made inroads towards elucidating the biological pathways and complex traits contributing to a wide range of conditions such as neurological, psychiatric & cardiometabolic disorders.² While such studies have provided evidence for genetically supported therapeutic targets & mechanisms,^{3,4} the application of statistical genetics methods to musculoskeletal⁵⁻¹⁷ and chronic pain conditions¹⁸⁻²⁵ as a strategy towards disentangling their causal mechanisms requires further comprehensive & concerted effort.

Previous clinical & epidemiological studies have found a range of psychiatric (e.g., stress, depression, trauma, anxiety^{26,27}), lifestyle (e.g., smoking,^{28,29} sedentary behaviour^{30,31}) and socioeconomic factors (e.g., income & education levels^{32,33}) associated with an increased risk of chronic pain, while medical conditions such as obesity³⁴ & cardiovascular diseases^{35,36} are also common comorbidities.³⁷ Large-scale GWAS have identified specific genetic loci in chronic pain conditions (e.g., back,^{12,19} neck/shoulder,¹⁵ knee pain⁹ & widespread pain^{14,20}) and demonstrated shared genetic bases with biopsychosocial traits (e.g., depression,^{19,20,27} post-traumatic stress disorder,²⁰ anorexia nervosa,³⁸ asthma,²⁰ brain morphology,¹⁸ poor sleep,^{8,19,39} obesity,⁵ low educational attainment^{19,40} & smoking^{19,40}). However, the nature of causal relationships between common chronic pain conditions and such multidimensional factors remains to be comprehensively examined.

Here we investigated the genetic correlations and causal relationships between eight regional chronic pain types and a comprehensive range of biological, psychological/psychiatric & social traits. In the largest phenome-wide study of chronic pain to date, we leveraged GWAS summary statistics in the Complex Traits Genetics Virtual Lab (CTG-VL — <u>http://genoma.io</u>)⁴¹ to delineate the putative genetic causal directions across common chronic pain conditions and >1,400 other traits/disorders.

Materials & Methods

Discovery GWAS Datasets for Chronic Pain

An overview of the analysis pipeline employed in the present study is shown in Figure 1. We performed GWAS of regional chronic pain types using the UK Biobank resource (application number 25331). The UK Biobank holds research ethics approval from the North West Multi-centre Research Ethics Committee (Manchester, United Kingdom). All participants provided written informed consent.

Chronic pain was defined using self-report answers to the following questions: *Have you* had [back pains / neck or shoulder pains / hip pains / knee pains / abdominal pains / facial pains / headaches / pain all over the body] for more than 3 months? (Questionnaire field ID: 6159). These questions could be answered with Yes, *No*, *Don't know*, or *Prefer not to answer*. Participants who responded Yes to a question were defined as cases for that specific chronic pain type (i.e., chronic back pain, chronic widespread pain [pain all over the body] etc.). We defined controls as participants who denied experiencing any pain for

more than three months (N=239,125). Participants who preferred not to answer were excluded from the study. The sample sizes of each GWAS were as follows: back pain (N=79,089); neck/shoulder pain (N=72,216); hip pain (N=41,677); knee pain (N=77,996); abdominal pain (N=21,285); facial pain (N=4,037); headache (N=39,283); widespread pain (N=6,063). Sample characteristics are further detailed in Supplementary Table S1.

We performed GWAS using REGENIE (v1.0.6.2)⁴² to test associations between the chronic pain types and genetic variants. REGENIE is a GWAS method that implements a logistic mixed model, whereby a genetic relationship between individuals is modelled as a random effect to account for cryptic relatedness. Covariates for the association analysis comprised sex, age, genotyping array and the top 10 principal components derived from genetic data. We used quality control procedures comprising exclusion of variants with: (i) minor allele frequency (MAF) < 0.005; (ii) imputation quality < 0.6; and (iii) deviation from Hardy-Weinberg equilibrium (P-value < 1 × 10⁻⁵). Subsequently, 11,172,285 single nucleotide polymorphisms (SNPs) remained for analysis. Participant data were excluded if their genotype-derived principal components 1 & 2 were more than six standard deviations from those of the 1000 Genomes European population. Following quality control, up to 441,088 participants remained in the GWAS.

Genetic Correlations

Genetic correlations were estimated between the regional chronic pain types and a wide range of other complex traits. Cross-trait bivariate linkage disequilibrium (LD) score regression was used — a method that leverages the expected relationship between LD and GWAS association statistics to estimate genetic correlations across traits while accounting for potential sample overlap across studies,⁴³ as implemented in CTG-VL.⁴¹ CTG-VL is a publicly available web platform compiled with >1,490 GWAS summary statistics that is used for running analyses across a comprehensive range of complex traits & disorders (mostly from UK Biobank releases). CTG-VIEW (https://view.genoma.io) is a data aggregator that enables direct queries, visualisations and storage of VL analysis results (and that from other data resources).

A genetic correlation (*rG*) ranges from -1 to 1 and quantifies the genome-wide genetic concordance between a pair of traits. Genetic correlation estimates approaching 1 or -1 indicate (respectively) that a proportion of genetic variants have concordant or divergent effects on both traits. Conversely, a genetic correlation that approaches 0 indicates there is little genetic concordance between the traits or that the genetic predictors of the traits are largely independent. A Benjamini-Hochberg false discovery rate (FDR < 5%) procedure was applied to genetic correlations between complex traits and each chronic pain type GWAS to account for multiple testing.

Latent Causal Variable Analyses

For trait pairs with non-zero genetic correlation (FDR < 5%), we employed latent causal variable (LCV) analyses to determine if the genetic correlation reflected a causal relationship or horizontal pleiotropy by estimating genetic causal proportion (GCP).^{44,45} The LCV method is robust to horizontal pleiotropy, which is ubiquitous in complex traits. LCV analyses can be conceptualised as assuming a latent 'causal' variable that mediates

the genetic correlation of two traits. Using mixed fourth moments of the bivariate effect size distribution across all SNPs in both GWAS, LCV estimates the posterior mean for GCP, which indicates the degree to which one trait is correlated with the latent 'causal' variable. GCP estimates range from -1 to 1: high positive values (GCP > 0.6) indicate greater partial genetic causality for Trait A (i.e., a chronic pain type) on Trait B (i.e., biological / psychological / social trait); whereas negative values (GCP < -0.6) indicate greater partial genetic causality for Trait B on Trait A. That is, GCP > 0.6 indicates that chronic pain likely has a causal effect on another particular trait, whereas GCP < -0.6 indicates a particular trait likely has a causal effect on chronic pain. Benjamini-Hochberg false discovery rate (FDR < 5%) was applied across GCPs for complex traits with each chronic pain type GWAS.

Results

Genetic Correlations & Latent Causal Variable Analyses

For each of the eight chronic pain types, details of significant genetic correlations with putative causal relationships are summarised in Figures 2–8 and Supplementary Figures S1 & S2, while *rG* and GCP data are reported in Supplementary Tables S2–S9. Complete genetic correlation and LCV analysis results for all 1,492 traits are presented in Supplementary Tables S10–S17.

From 11,932 trait pairs, we identified 5,942 significant genetic correlations (which corroborate many reported phenotypic associations from previous clinical studies), of which 570 trait pairs showed evidence of a causal association (|GCP| > 0.6; 5% false

discovery rate). Of these, 488 traits had genetic casual effects on chronic pain, while the remaining 82 traits were affected by pain.

Comparisons of *rG* and significant GCP results across the eight chronic pain types are presented in Figures 2 & 3. Overall, the direction of the genetic correlations between the complex traits and chronic pain were broadly consistent across all eight types. There were eight instances where the direction of genetic causal relationships (denoted by GCP > 0.6 or < -0.6) differed between the chronic pain types (Supplementary Table S18). Additional *rG* estimates for the eight chronic pain types are presented in Supplementary Table S19, including significant genetic correlations between each type, whereby the analysis method accounted for the overlapping samples.

Key Results Across Chronic Pain Types

Significant *rG* (5% FDR) and GCP estimates (< -0.6; 5% FDR) were observed for musculoskeletal pathologies, which showed genetic causal effects on chronic back, neck/shoulder, hip, knee, abdominal, headaches and widespread pain, including local sites (e.g., coxarthrosis of the hip & chronic hip pain *rG* [S.E.] = 0.42 [0.06]; GCP [S.E.] = -0.90 [0.08]) as well as remote sites (e.g., other intervertebral disc disorders & chronic knee pain *rG* [S.E.] = 0.61 [0.12], GCP [S.E.] = -0.79 [0.16]) (Figures 4–8, Supplementary Figures S1 & S2, Supplementary Tables S2–S9). Cardiovascular disease-associated traits affected each of the chronic pain types (e.g., heart failure contributes to back pain [*rG* (S.E.) = 0.22 (0.09); GCP (S.E.) = -0.73 (0.16)] and hip pain [*rG* (S.E.) = 0.30 (0.11); GCP (S.E.) = -0.62 (0.24)]), while certain chronic pain types (i.e., neck/shoulder,

abdominal, facial & widespread pain) also affected cardiovascular traits such as ischaemic heart disease (neck/shoulder pain rG [S.E.] = 0.30 [0.04], GCP [S.E.] = 0.71 [0.22]; facial pain rG [S.E.] = 0.26 [0.09], GCP [S.E.] = 0.64 [0.22]). A number of chronic pain types (i.e., back, neck/shoulder, hip, knee, abdominal & headaches) contributed to medication use for cholesterol, blood pressure, diabetes or exogenous hormones. Chronic headaches and widespread pain also impacted the use of analgesics (i.e., paracetamol, ibuprofen, aspirin; and paracetamol, respectively), while the use of various medications (e.g., analgesics, cardiovascular drugs) affected chronic back, neck/shoulder, hip, knee, abdominal, headache and widespread pain.

Psychological traits and psychiatric diagnoses also had genetic causal effects on chronic pain types. Notably: (i) depression and anxiety-associated traits increased the risk of chronic back, neck/shoulder, hip, knee, abdominal, headache and widespread pain; (ii) mania-associated traits increased the risk of chronic back, neck/shoulder, hip, knee, facial and widespread pain; and (iii) substance abuse/addiction-associated traits increased the risk of chronic back, neck/shoulder, hip, knee, facial and widespread pain; and (iii) substance abuse/addiction-associated traits increased the risk of chronic back, neck/shoulder, hip, knee, abdominal, facial and widespread pain. Traits concerning bipolar disorder and psychosis respectively increased the risk of hip, knee and widespread pain; and of neck/shoulder, knee and facial pain. Chronic back pain, facial pain and headaches had genetic causal effects upon traits concerning depression, anxiety and mania (significant rG [5% FDR] and GCP > 0.6 [5% FDR]). Traits specific to occupations demonstrated genetic causal contributions to back, neck/shoulder, hip, knee, abdominal and widespread pain (e.g., receptionist & chronic back pain rG [S.E.] = 0.38 [0.17]; GCP [S.E.] = -0.97 [0.04]), while traits relating to work environment increased the

risk of all eight chronic pain types (e.g., *'Workplace had a lot of diesel exhaust: Often'* and chronic widespread pain rG [S.E.] = 0.60 [0.15]; GCP [S.E.] = -0.81 [0.15]).

Region Specific Summaries

Additional results on the key findings for each pain type are presented in the Supplementary Results.

Discussion

The multifactorial nature of chronic pain conditions means that assessing their aetiological relationships is challenging due to the large sample sizes and long follow-up timeframes required for multivariate longitudinal analyses. Large-scale genetic datasets adequately powered for GWAS, along with statistical genetics methods developed for investigating causality (e.g., LCV, Mendelian randomization [MR]), present a way forward. The primary findings of this data-driven study provide quantitative genetic evidence for a range of shared biopsychosocial factors demonstrating causal effects upon eight common types of chronic pain. Certain clinical factors (e.g., musculoskeletal pathology, medical comorbidities), psychological/psychiatric traits (e.g., depression, trauma, anxiety, mania) and socioeconomic status (e.g., occupation) increased the risk of chronic pain types. The results also indicated genetic causal effects of chronic pain upon other traits such as increased medication use and increased risk of cardiovascular disease & depression. The current study has characterised the multidimensional casual traits and substantially narrowed down the range of genetically supported risk and protective factors for chronic pain. This work lays the foundation for further translational studies to identify the

underlying causal genetic variants and pathophysiological pathways for developing novel diagnostic & therapeutic technologies and strategies.

Overall, the directions of genetic correlations were consistent across an array of biopsychosocial traits and common chronic pain types. The vast majority of significant genetic causal directions between them were also consistent, while only a small minority differed across the chronic pain types — which suggests an underlying universal genetic core that is shared with these complex traits. Significant genetic correlations found between each of the eight chronic pain types provide additional evidence of a shared genetic signature, which builds upon recent studies^{5,46} and earlier proposals⁴⁷ pursuing this empirical demonstration. The biopsychosocial traits identified in the current study can also serve as candidates for patient classification, risk stratification and pain phenotyping in the clinical management of chronic pain conditions.⁷ Furthermore, based on the precedent for genetically supported therapeutic targets,^{3,4} the identified traits with genetic causal effects are potential targets in the clinical management of chronic pain as our results provide corroborating genetic evidence for current treatment & prevention strategies (e.g., weight-loss in knee osteoarthritis⁴⁸ & targeting post-traumatic stress after injury^{49,50}, respectively).

The results also indicate corroborating genetic evidence that musculoskeletal pathologies (e.g., intervertebral disc disorders in back pain, spondylopathies in neck/shoulder pain, coxarthrosis in hip pain) and visceral pathologies (e.g., renal & ureteric calculi) contribute to chronic pain. We found genetic causal effects of painful pathologies at remote sites

upon regional chronic pain types (e.g., shoulder impingement on chronic hip pain), which is consistent with a shared genetic signature and associated predisposition to chronic pain (i.e., an underlying genetic predisposition to musculoskeletal shoulder pathology also contributes to increased risk of chronic hip pain).

Not surprisingly, the results indicate that certain chronic pain types (i.e., headaches & widespread pain) contribute to use of analgesic medications (i.e., paracetamol, ibuprofen, aspirin; and paracetamol, respectively). Interestingly, various drugs used in the treatment of pain (e.g., opioids, non-steroidal anti-inflammatory drugs, antidepressants²⁷), cardiovascular disease (e.g., statins, beta-blockers) and gastro-oesophageal reflux showed an effect of increased risk for various chronic pain types. While some of these may reflect a genetic correlation between pain and problematic opioid use,⁵¹ the effect of medication use on increasing the risk of chronic pain may also be attributable to an indirect causal effect. For example, an unobserved trait (e.g., symptom/disease), which increases the likelihood of both medication use and a chronic pain type, could create an apparent casual effect between that medication and the pain type. That is, medication use (e.g., analgesics) could simply serve as a proxy for conditions that cause pain or that are commonly co-morbid with chronic pain. For instance, antidepressants may reflect the relationship between chronic pain and depression,²⁷ or conversely, the use of antidepressants to treat chronic pain conditions.^{52,53}

Our findings indicate that while pain conditions and psychological traits (e.g., depression) are frequently co-morbid at a phenotypic level, the pattern of causal relationships between

them are heterogenous across the various chronic pain types. For instance, we observed genetic evidence of causal relationships across both directions between depressionassociated traits and chronic headaches & back pain (i.e., a proportion of relationships are pain \rightarrow depression and others are depression \rightarrow pain [Supplementary Tables S2, S8]). In contrast, depression-associated traits exclusively showed effects on chronic neck/shoulder, hip, knee, abdominal and widespread pain (i.e., depression \rightarrow pain only [Supplementary Tables S3–6, S9]), consistent with evidence for (modest) effects of treatments targeting depression upon pain & disability in such conditions (e.g., serotoninnoradrenaline reuptake inhibitors for knee osteoarthritis⁵³). Conversely, chronic facial pain increased the risk of seeking care for depression (i.e., pain \rightarrow depression only [Supplementary Table S7]). These findings are broadly consistent with other genetic studies concerning depression and chronic pain, which have shown genetic causal relationships between chronic pain and depression, spanning both depression \rightarrow pain pathways⁵⁴⁻⁵⁸ and pain \rightarrow depression pathways.^{20,52,55,59} Taken together, our results and previous findings^{19,20,27,54,55} raise further intriguing hypotheses, such as that either or both causal directions may exist on a patient sub-group basis.⁵² Our LCV results also implicate a history of trauma or stress — including death of a close relative in last two years; being adopted as a child; sexual assault; marital separation; and military service - as genetic causal factors for various chronic pain types. Phenotypic studies indicate that trauma^{60,61} or post-traumatic stress⁶² are risk factors for development of chronic pain.⁶³ Our LCV results provide convergent evidence for targeting post-traumatic stress symptoms in treatment of pain, such as recently reported in a randomised controlled trial for whiplashassociated disorder,⁴⁹ which showed reductions in pain and disability through

improvements in stress, depression and post-traumatic stress.⁵⁰ In addition to depression and trauma, traits concerning anxiety, psychosis, bipolar disorder and mania showed genetic causal effects on several chronic pain types.

Socioeconomic factors also demonstrated genetic causal effects on a range of chronic pain types. Broadly, occupational traits associated with lower socioeconomic status (e.g., elementary office worker) contributed to increased chronic pain risk, whereas those with higher incomes (e.g., software engineer) were protective against chronic pain. Socioeconomic status may affect pain risk³³ through a range of potential pathways, including increased likelihood of: (i) lower educational attainment (associated with use of less effective pain coping strategies⁶⁴); (ii) various negative health behaviours (e.g., low physical activity & smoking⁶⁵); (iii) early life adverse events⁶⁶; and (iv) impaired access to healthcare.⁶⁷ Accordingly, interventions and policies targeting socioeconomic inequality may have beneficial downstream effects on the broader community burden of chronic pain.

Various medical conditions such as cardiovascular, gastrointestinal & respiratory diagnoses demonstrated genetic correlations and genetic causal relationships with chronic pain types. Notably, cardiovascular-related traits showed heterogeneous associations. For example, heart failure contributed to chronic back and hip pain, whereas neck/shoulder and facial pain increased the risk of ischaemic heart disease. Numerous cardiovascular risk factors showed genetic causal contributions to chronic pain such as obesity (i.e., hip, knee & widespread pain), low-density lipoprotein/Apolipoprotein B (i.e.,

back, neck/shoulder, hip & knee pain) and triglycerides (i.e., facial & widespread pain). These findings are consistent with phenotypic relationships between chronic pain and cardiovascular diagnoses/mortality, which may reflect other associations between chronic pain and cardiac risk factors (e.g., smoking).³⁷

A limitation of the current study is the minimal clinical details used to define regional chronic pain (i.e., a self-report questionnaire regarding presence of pain for >3 months at a body site). However, this minimal phenotyping approach enables acquisition of large-scale data with sufficient power for GWAS and post-GWAS analyses of causal relationships. As the chronic pain and complex trait GWAS data were mostly derived from the UK Biobank, we employed LCV analyses rather than a more traditional approach (e.g., MR) because overlapping samples in the latter can bias estimates towards the confounded associations.⁶⁸ Although the LCV method is not able to detect bidirectional relationships between two individual traits (e.g., chronic pain \rightarrow Trait A and Trait A \rightarrow chronic pain), its current application in comprehensive phenome-wide analyses — particularly for complex disorders such as chronic pain — is an efficient & effective strategy upon which to follow up with traditional approaches (e.g., MR, genomic structural equation modelling⁶⁹) targeting the genetic causal traits delineated in the current study.

Further work is required including: **(i)** genetic epidemiology studies collecting data on more specific chronic pain diagnoses, clinical traits (e.g., pro- & anti-nociceptive phenotypes, quantitative sensory testing,⁷⁰⁻⁷³ medication/treatment responses^{52,74}) and epigenetic factors⁷⁵ (e.g., early life stress, physical activity); **(ii)** replication in other large

genotyped datasets,^{5,19} particularly population samples with non-European ancestry; and **(iii)** incorporating putative transdiagnostic subtypes and genetic risk stratification of placebo/control groups in clinical trials of chronic pain interventions.^{3,4,27,52,76}

Our LCV analysis of >1,400 biopsychosocial complex traits has leveraged the underlying genetic variant data to provide a comprehensive characterisation of risk & protective factors across common regional chronic pain conditions, and in turn, testable hypotheses for further targeted interrogation. It has also provided corroborating genetic evidence for current treatment approaches (e.g., targeting psychological traits), which lays the foundation for further translational studies into developing more effective multidisciplinary care frameworks and enhancing patient outcomes.

Data Statement

Complex trait GWAS summary statistics are publicly available. Links to reference and download each of these are available in CTG-VL (<u>https://vl.genoma.io</u>) and CTG-VIEW (<u>https://view.genoma.io</u>). Complete GWAS summary statistics and results from downstream analyses for all the chronic pain types reported in the current study (Supplementary Table S1) are available at CTG-VIEW.

References

1. Cieza A, Causey K, Kamenov K, Hanson SW, Chatterji S, Vos T. Global estimates of the need for rehabilitation based on the Global Burden of Disease study

2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. Dec 19 2021;396(10267):2006-2017. doi:10.1016/s0140-6736(20)32340-0

2. Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug repurposing. *Nature Reviews Genetics*. 2021/10/01 2021;22(10):658-671. doi:10.1038/s41576-021-00387-z

3. King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. *PLOS Genet*. 2019;15(12):e1008489. doi:10.1371/journal.pgen.1008489

4. Ginsburg GS, Cavallari LH, Chakraborty H, et al. Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. *Genetics Med.* 2021/07/01 2021;23(7):1185-1191. doi:10.1038/s41436-021-01118-9

5. Boer CG, Hatzikotoulas K, Southam L, et al. Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations. *Cell*. Sep 2 2021;184(18):4784-4818.e17. doi:10.1016/j.cell.2021.07.038

 Vincent TL. Of mice and men: converging on a common molecular understanding of osteoarthritis. *Lancet Rheumatol.* 2020;2(10):e633-e645. doi:10.1016/S2665-9913(20)30279-4

7. Nijs J, George SZ, Clauw DJ, et al. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. *The Lancet Rheumatology*. 2021;3(5):e383-e392. doi:10.1016/S2665-9913(21)00032-1

8. Zhang Y, Grant RA, Shivakumar MK, et al. Genome-wide Association Analysis Across 16,956 Patients Identifies a Novel Genetic Association Between BMP6, NIPAL1,

CNGA1 and Spondylosis. *Spine (Phila Pa 1976)*. Jun 1 2021;46(11):E625-e631. doi:10.1097/brs.000000000003880

9. Meng W, Adams MJ, Palmer CNA, et al. Genome-wide association study of knee pain identifies associations with GDF5 and COL27A1 in UK Biobank. *Communications Biology*. 2019/08/28 2019;2(1):321. doi:10.1038/s42003-019-0568-2

10. Rahman MS, Winsvold BS, Chavez Chavez SO, et al. Genome-wide association study identifies RNF123 locus as associated with chronic widespread musculoskeletal pain. *Annals of the Rheumatic Diseases*. 2021:annrheumdis-2020-219624.

doi:10.1136/annrheumdis-2020-219624

11. Suri P, Palmer MR, Tsepilov YA, et al. Genome-wide meta-analysis of 158,000 individuals of European ancestry identifies three loci associated with chronic back pain. *PLoS Genet*. Sep 2018;14(9):e1007601. doi:10.1371/journal.pgen.1007601

12. Freidin MB, Tsepilov YA, Stanaway IB, et al. Sex- and age-specific genetic analysis of chronic back pain. *Pain*. Apr 1 2021;162(4):1176-1187.

doi:10.1097/j.pain.000000000002100

13. Bortsov AV, Parisien M, Khoury S, et al. Genome-wide analysis identifies significant contribution of brain-expressed genes in chronic, but not acute, back pain. *medRxiv*. 2020:2020.09.04.20187575. doi:10.1101/2020.09.04.20187575

14. Johnston KJA, Ward J, Ray PR, et al. Sex-stratified genome-wide association study of multisite chronic pain in UK Biobank. *PLOS Genet*. 2021;17(4):e1009428. doi:10.1371/journal.pgen.1009428

Meng W, Chan BW, Harris C, et al. A genome-wide association study finds
genetic variants associated with neck or shoulder pain in UK Biobank. *Hum Mol Genet*.
May 28 2020;29(8):1396-1404. doi:10.1093/hmg/ddaa058

16. Hartley A, Sanderson E, Granell R, et al. Using multivariable Mendelian randomization to estimate the causal effect of bone mineral density on osteoarthritis risk, independent of body mass index. *medRxiv*. 2021:2021.03.22.21253803.

doi:10.1101/2021.03.22.21253803

 Gao S, Zhou H, Luo S, et al. Investigating the Causal Relationship Between Physical Activity and Chronic Back Pain: A Bidirectional Two-Sample Mendelian Randomization Study. Original Research. *Frontiers in Genetics*. 2021-December-20 2021;12doi:10.3389/fgene.2021.758639

18. Farrell SF, Campos AI, Kho PF, et al. Genetic basis to structural grey matter associations with chronic pain. *Brain*. 2021;144(12):3611–3622.

doi:10.1093/brain/awab334

19. Freidin MB, Tsepilov YA, Palmer M, et al. Insight into the genetic architecture of back pain and its risk factors from a study of 509,000 individuals. *PAIN*. Jun 2019;160(6):1361-1373. doi:10.1097/j.pain.00000000001514

20. Johnston KJA, Adams MJ, Nicholl BI, et al. Genome-wide association study of multisite chronic pain in UK Biobank. *PLoS Genet*. Jun 2019;15(6):e1008164. doi:10.1371/journal.pgen.1008164

21. Lobo JJ, McLean SA, Tungate AS, et al. Polygenic risk scoring to assess genetic overlap and protective factors influencing posttraumatic stress, depression, and chronic

pain after motor vehicle collision trauma. *Translational Psychiatry*. 2021/06/29 2021;11(1):359. doi:10.1038/s41398-021-01486-5

22. van Reij RRI, Voncken JW, Joosten EAJ, van den Hoogen NJ. Polygenic risk scores indicates genetic overlap between peripheral pain syndromes and chronic postsurgical pain. *neurogenetics*. 2020/07/01 2020;21(3):205-215. doi:10.1007/s10048-020-00614-5

23. Veluchamy A, Hébert HL, van Zuydam NR, et al. Association of Genetic Variant at Chromosome 12q23.1 With Neuropathic Pain Susceptibility. *JAMA Netw Open*. Dec 1 2021;4(12):e2136560. doi:10.1001/jamanetworkopen.2021.36560

24. Wiberg A, Ng M, Schmid AB, et al. A genome-wide association analysis identifies
16 novel susceptibility loci for carpal tunnel syndrome. *Nature communications*.
2019/03/04 2019;10(1):1030. doi:10.1038/s41467-019-08993-6

25. Cardoso JV, Perini JA, Machado DE, Pinto R, Medeiros R. Systematic review of genome-wide association studies on susceptibility to endometriosis. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2020/12/01/ 2020;255:74-82.

doi:https://doi.org/10.1016/j.ejogrb.2020.10.017

26. Velly AM, Mohit S. Epidemiology of pain and relation to psychiatric disorders.

Prog Neuropsychopharmacol Biol Psychiatry. Dec 20 2018;87(Pt B):159-167.

doi:10.1016/j.pnpbp.2017.05.012

27. Roughan WH, Campos AI, García-Marín LM, et al. Comorbid Chronic Pain and Depression: Shared Risk Factors and Differential Antidepressant Effectiveness. *Front Psychiatry*. 2021;12:643609. doi:10.3389/fpsyt.2021.643609

 Zvolensky MJ, McMillan KA, Gonzalez A, Asmundson GJ. Chronic musculoskeletal pain and cigarette smoking among a representative sample of Canadian adolescents and adults. *Addictive behaviors*. Nov 2010;35(11):1008-12. doi:10.1016/j.addbeh.2010.06.019

29. Dai Y, Huang J, Hu Q, Huang L, Wu J, Hu J. Association of Cigarette Smoking with Risk of Chronic Musculoskeletal Pain: A Meta-Analysis. *Pain Physician*. Dec 2021;24(8):495-506.

30. Nilsen TI, Holtermann A, Mork PJ. Physical exercise, body mass index, and risk of chronic pain in the low back and neck/shoulders: longitudinal data from the Nord-Trondelag Health Study. *American journal of epidemiology*. Aug 1 2011;174(3):267-73. doi:10.1093/aje/kwr087

31. Lin CC, McAuley JH, Macedo L, Barnett DC, Smeets RJ, Verbunt JA. Relationship between physical activity and disability in low back pain: a systematic review and meta-analysis. *Pain*. Mar 2011;152(3):607-613.

doi:10.1016/j.pain.2010.11.034

32. Macfarlane GJ, Beasley M, Smith BH, Jones GT, Macfarlane TV. Can large surveys conducted on highly selected populations provide valid information on the epidemiology of common health conditions? An analysis of UK Biobank data on musculoskeletal pain. *British Journal of Pain*. 2015/11/01 2015;9(4):203-212.

doi:10.1177/2049463715569806

Prego-Domínguez J, Khazaeipour Z, Mallah N, Takkouche B. Socioeconomic status and occurrence of chronic pain: a meta-analysis. *Rheumatology*.
 2021;60(3):1091-1105. doi:10.1093/rheumatology/keaa758

34. Wong CK, Mak RY, Kwok TS, et al. Prevalence, Incidence, and Factors Associated With Non-Specific Chronic Low Back Pain in Community-Dwelling Older Adults Aged 60 Years and Older: A Systematic Review and Meta-Analysis. *J Pain*. Apr 2022;23(4):509-534. doi:10.1016/j.jpain.2021.07.012

35. Fayaz A, Ayis S, Panesar SS, Langford RM, Donaldson LJ. Assessing the relationship between chronic pain and cardiovascular disease: A systematic review and meta-analysis. *Scand J Pain*. Oct 2016;13:76-90. doi:10.1016/j.sjpain.2016.06.005

36. Tesarz J, Eich W, Baumeister D, Kohlmann T, D'Agostino R, Schuster AK.

Widespread pain is a risk factor for cardiovascular mortality: results from the

Framingham Heart Study. Eur Heart J. May 21 2019;40(20):1609-1617.

doi:10.1093/eurheartj/ehz111

37. Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. *Br J Anaesth*. Aug

2019;123(2):e273-e283. doi:10.1016/j.bja.2019.03.023

38. Johnson JS, Cote AC, Dobbyn A, et al. The Phenome-wide Consequences of Anorexia Nervosa Genes. *medRxiv*. 2021:2021.02.12.21250941.

doi:10.1101/2021.02.12.21250941

39. Broberg M, Karjalainen J, FinnGen, Ollila HM. Mendelian randomization highlights insomnia as a risk factor for pain diagnoses. *Sleep*. 2021;44(7):zsab025. doi:10.1093/sleep/zsab025

40. Lundberg M, Campos AI, Farrell SF, et al. Genetic, lifestyle and environmental risk factors for chronic pain revealed through GWAS. *bioRxiv*.

2020;doi:10.1101/2020.05.26.115568

41. Cuéllar-Partida G, Lundberg M, Kho PF, et al. Complex-Traits Genetics Virtual Lab: A community-driven web platform for post-GWAS analyses. *bioRxiv*. 2019:518027. doi:10.1101/518027

42. Mbatchou J, Barnard L, Backman J, et al. Computationally efficient wholegenome regression for quantitative and binary traits. *Nature genetics*. 2021/07/01 2021;53(7):1097-1103. doi:10.1038/s41588-021-00870-7

43. Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. *Nature genetics*. Nov 2015;47(11):1236-41.

doi:10.1038/ng.3406

44. Haworth S, Kho PF, Holgerson PL, et al. Assessment and visualization of phenome-wide causal relationships using genetic data: an application to dental caries and periodontitis. *European Journal of Human Genetics*. 2021/02/01 2021;29(2):300-308. doi:10.1038/s41431-020-00734-4

45. O'Connor LJ, Price AL. Distinguishing genetic correlation from causation across 52 diseases and complex traits. *Nature genetics*. Dec 2018;50(12):1728-1734. doi:10.1038/s41588-018-0255-0

46. Meng W, Adams MJ, Reel P, et al. Genetic correlations between pain phenotypes and depression and neuroticism. *European Journal of Human Genetics*. 2020/03/01 2020;28(3):358-366. doi:10.1038/s41431-019-0530-2

47. Diatchenko L, Fillingim RB, Smith SB, Maixner W. The phenotypic and genetic signatures of common musculoskeletal pain conditions. *Nature Reviews Rheumatology*. 2013/06/01 2013;9(6):340-350. doi:10.1038/nrrheum.2013.43

48. Arden NK, Perry TA, Bannuru RR, et al. Non-surgical management of knee
osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. *Nat Rev Rheumatol.*Jan 2021;17(1):59-66. doi:10.1038/s41584-020-00523-9

49. Sterling M, Smeets R, Keijzers G, Warren J, Kenardy J. Physiotherapistdelivered stress inoculation training integrated with exercise versus physiotherapy exercise alone for acute whiplash-associated disorder (StressModex): a randomised controlled trial of a combined psychological/physical intervention. *British Journal of Sports Medicine*. 2019;doi:10.1136/bjsports-2018-100139

50. Elphinston RA, Sterling M, Kenardy J, Smeets R, Armfield NR. The mechanisms of effect of a physiotherapist-delivered integrated psychological and exercise intervention for acute whiplash-associated disorders: secondary mediation analysis of a randomized controlled trial. *Pain Rep.* Sep-Oct 2020;5(5):e835.

doi:10.1097/pr9.000000000000835

51. Sanchez-Roige S, Fontanillas P, Jennings MV, et al. Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry. *Molecular Psychiatry*. 2021/11/02 2021;doi:10.1038/s41380-021-01335-3

52. Campos AI, Ngo TT, Medland SE, et al. Genetic risk for chronic pain is associated with lower antidepressant effectiveness: Converging evidence for a depression subtype. *Australian & New Zealand Journal of Psychiatry*. 2021:00048674211031491. doi:10.1177/00048674211031491

53. Ferreira GE, McLachlan AJ, Lin C-WC, et al. Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. *BMJ*. 2021;372:m4825. doi:10.1136/bmj.m4825

54. Mocci E, Ward K, Dorsey SG, Ament SA. GWAS meta-analysis reveals dual neuronal and immunological etiology for pain susceptibility. *medRxiv*.

2021:2021.08.23.21262510. doi:10.1101/2021.08.23.21262510

55. Barowsky S, Jung J-Y, Nesbit N, et al. Cross-Disorder Genomics Data Analysis Elucidates a Shared Genetic Basis Between Major Depression and Osteoarthritis Pain. Original Research. *Frontiers in Genetics*. 2021-September-16

2021;12(1276)doi:10.3389/fgene.2021.687687

56. Wu Y, Byrne EM, Zheng Z, et al. Genome-wide association study of medicationuse and associated disease in the UK Biobank. *Nature communications*. 2019/04/23 2019;10(1):1891. doi:10.1038/s41467-019-09572-5

57. Adewuyi EO, Mehta D, Sapkota Y, et al. Genetic analysis of endometriosis and depression identifies shared loci and implicates causal links with gastric mucosa abnormality. *Hum Genet*. Mar 2021;140(3):529-552. doi:10.1007/s00439-020-02223-6

58. Tang B, Meng W, Hägg S, Burgess S, Jiang X. Reciprocal interaction between depression and pain: results from a comprehensive bidirectional Mendelian randomization study and functional annotation analysis. *PAIN*. 2022;163(1)

59. García-Marín LM, Campos AI, Martin NG, Cuéllar-Partida G, Rentería ME. Phenome-wide analysis highlights putative causal relationships between self-reported migraine and other complex traits. *The Journal of Headache and Pain*. 2021/07/08 2021;22(1):66. doi:10.1186/s10194-021-01284-w

60. Burke NN, Finn DP, McGuire BE, Roche M. Psychological stress in early life as a predisposing factor for the development of chronic pain: Clinical and preclinical evidence and neurobiological mechanisms. <u>https://doi.org/10.1002/jnr.23802</u>. *Journal of Neuroscience Research*. 2017/06/01 2017;95(6):1257-1270.

doi:https://doi.org/10.1002/jnr.23802

61. Ulirsch JC, Ballina LE, Soward AC, et al. Pain and somatic symptoms are sequelae of sexual assault: results of a prospective longitudinal study. *Eur J Pain*. Apr 2014;18(4):559-66. doi:10.1002/j.1532-2149.2013.00395.x

62. Sterling M, Jull G, Vicenzino B, Kenardy J, Darnell R. Physical and psychological factors predict outcome following whiplash injury. *PAIN*. 2005;114:141-148.

63. McLean SA, Ressler K, Koenen KC, et al. The AURORA Study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure. *Mol Psychiatry*. Feb 2020;25(2):283-296. doi:10.1038/s41380-019-0581-3

64. Cano A, Mayo A, Ventimiglia M. Coping, Pain Severity, Interference, and Disability: The Potential Mediating and Moderating Roles of Race and Education. *The Journal of Pain*. 2006/07/01/ 2006;7(7):459-468.

doi:https://doi.org/10.1016/j.jpain.2006.01.445

Nandi A, Glymour MM, Subramanian SV. Association Among Socioeconomic
Status, Health Behaviors, and All-Cause Mortality in the United States. *Epidemiology*.
2014;25(2)

66. Assari S. Family Socioeconomic Status and Exposure to Childhood Trauma: Racial Differences. *Children (Basel)*. 2020;7(6):57. doi:10.3390/children7060057

67. McMaughan DJ, Oloruntoba O, Smith ML. Socioeconomic Status and Access to Healthcare: Interrelated Drivers for Healthy Aging. *Front Public Health*. 2020;8:231-231. doi:10.3389/fpubh.2020.00231

68. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in twosample Mendelian randomization. *Genet Epidemiol*. Nov 2016;40(7):597-608.

doi:10.1002/gepi.21998

69. Rosoff DB, Smith GD, Lohoff FW. Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders: A Multivariable Mendelian Randomization Analysis. *JAMA Psychiatry*. Feb 1 2021;78(2):151-160. doi:10.1001/jamapsychiatry.2020.3554

70. White L, Smith AD, Farrell SF. Associations between resting heart rate, resting blood pressure, psychological variables and pain processing in chronic whiplash-associated disorder: a cross-sectional study. *Pain Med.* May 19

2022;doi:10.1093/pm/pnac075

71. Zhu G, Böttger K, Slater H, et al. Concurrent validity of a low-cost and timeefficient clinical sensory test battery to evaluate somatosensory dysfunction *Eur J Pain*. 2019;23:1826-38.

72. Schmid AB, Adhikari K, Ramirez-Aristeguieta LM, et al. Genetic components of human pain sensitivity: a protocol for a genome-wide association study of experimental pain in healthy volunteers. *BMJ Open*. 2019;9(4):e025530. doi:10.1136/bmjopen-2018-025530

73. Fontanillas P, Kless A, Bothmer J, Tung JY. Genome-wide association study of pain sensitivity assessed by questionnaire and the cold pressor test. *PAIN*.

2021;doi:10.1097/j.pain.000000000002568

Li S, Poelmans G, van Boekel RLM, Coenen MJH. Genome-wide association study of nociceptive musculoskeletal pain treatment response in UK Biobank. *medRxiv*.
2022:2022.01.04.22268719. doi:10.1101/2022.01.04.22268719

75. Polli A, Godderis L, Ghosh M, Ickmans K, Nijs J. Epigenetic and miRNA

Expression Changes in People with Pain: A Systematic Review. 2020. p. 763-780.

76. Brown MA, Xu H, Li Z. Genetics and the axial spondyloarthritis spectrum.

Rheumatology. 2020;59(Supplement_4):iv58-iv66. doi:10.1093/rheumatology/keaa464

Figures

Figure 1: Phenome-wide analysis pipeline for eight types of regional chronic pain with 1,492 other complex traits. Genome-wide association studies (GWAS) were performed for chronic back, neck/shoulder, hip, knee, abdominal, facial, headache and widespread pain. These results and publicly available GWAS summary statistics for 1,492 complex traits were uploaded into the Complex Traits Genetics Virtual Lab (CTG-VL), which along with CTG-VIEW were used to perform cross-trait linkage disequilibrium-score (LD-score) regression and latent causal variable analyses to respectively calculate genetic correlations (*rG*) and genetic causal proportions (GCP). The 570 traits with significant GCPs were categorised as per Figures 4–7 (x-axis) and Supplementary Tables S2–S9. This strategy enables the identification & targeting of genetically supported risk & protective factors for chronic pain types in further translationally focused studies (e.g., interventional trials).



Figure 2: Scatterplot matrix showing the genetic correlations (*rG*) between chronic pain and 1,492 complex traits across the eight regional pain types. The genetic correlations were broadly consistent across these types, which indicates the genetic variants specific to each of the 1,492 complex traits had consistent correlations (positive or negative) with the genetic variants associated with each of the chronic pain types. This pattern of results points toward a shared genetic basis across these chronic pain types, which may partly account for both an increased risk of developing chronic pain (more generally) and its commonly comorbid biopsychosocial traits.



Figure 3: Scatterplot matrix showing 570 significant genetic causal proportions (GCPs) between chronic pain and 1,492 complex traits across the eight regional pain types wherein the LCV analysis method took into account the overlapping samples. There were eight instances where the direction of causal relationships (denoted by GCP > 0.6 or < - 0.6) differed between the pain types as detailed in Supplementary Table S18. These included psychological traits (e.g., concerning mania/irritability), family history/social factors, musculoskeletal pathology & other clinical traits. Such differences in the traits' casual directions across pain types may reflect broader multi-directional dynamic relationships (e.g., mania/irritability both impacting & being affected by chronic pain) or may be more specific to regional pain types (e.g., arthrosis contributing to hip pain as joint pathology cf. abdominal pain contributing to arthrosis indirectly, such as via physical inactivity or another pathway). The otherwise broadly consistent direction of causal relationships with complex traits across these common chronic pain types supports a shared biopsychosocial genetic basis.



Figure 4: Genetic correlations (rG) for traits with significant genetic causal proportion (GCP) estimates indicative of a causal effect upon regional chronic pain types (GCP < -0.6, 5% false discovery rate) are shown across the range of complex trait categories (xaxis). Data are presented for (A) chronic back pain, (B) neck/shoulder pain, (C) hip pain and (D) knee pain. A broad range of traits demonstrate evidence of genetic causal effects contributing to an increased risk of chronic pain — notably, psychological traits (e.g., depression on back, neck/shoulder, hip & knee pain), socioeconomic factors (e.g., workrelated traits on back, neck/shoulder, hip & knee pain), musculoskeletal pathology (e.g., spondylopathies on neck/shoulder pain), medication use (e.g., dihydrocodeine on back pain) and addiction (e.g., smoking on back, neck/shoulder, hip & knee pain). Other traits had an apparent protective effect against these chronic pain types such as vegetable & dairy consumption work-associated factors and certain (e.g., software programmer/engineer and reduced risk of neck/shoulder pain — Supplementary Table S3 & Supplementary Results 2). BMI: body mass index; COPD: chronic obstructive pulmonary disease.



Figure 5: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of a causal effect upon regional chronic pain types (GCP < - 0.6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic abdominal pain, (**B**) facial pain, (**C**) headaches and (**D**) widespread pain. A broad range of traits demonstrate evidence of genetic causal effects on these pain types, including psychological (e.g., depression, trauma/stress, mania and/or anxiety on headaches, abdominal, facial & widespread pain), gastrointestinal (e.g., colitis on headaches, abdominal, facial & widespread pain). Other traits had an apparent protective effect against certain chronic pain types such as dairy & cheese consumption (abdominal & widespread pain). COPD: chronic obstructive pulmonary disease; DVT: deep vein thrombosis; ECG: electrocardiogram; GGT: gamma-glutamyl transferase.



Figure 6: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of being affected by chronic pain (GCP > 0.6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic back pain, (**B**) neck/shoulder pain, (**C**) hip pain and (**D**) knee pain. While there are fewer instances of these regional chronic pain affecting other traits than *vice versa* (Fig. 4), the results suggest these chronic pain types have genetic causal effects contributing to increased medication use (i.e., for cholesterol, blood pressure, diabetes or exogenous hormones) and an increased risk of cardiovascular disease (i.e., neck/shoulder pain on ischemic heart disease) along with other disorders (e.g., back pain on depression).



Figure 7: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of being affected by chronic pain (GCP > 0.6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic abdominal pain, (**B**) facial pain, (**C**) headaches and (**D**) widespread pain. Notably, facial pain showed effects on a wide range of traits including dietary patterns (e.g., reduced muesli, ground coffee), psychological factors (e.g., increased depression, anxiety) and an increased risk of neurological conditions (e.g., mononeuropathies, carpal tunnel syndrome), whereas abdominal pain particularly contributed to an increased risk of cardiovascular disease (e.g., hypertension). Chronic headache had genetic effects contributing to increased analgesic use (i.e., paracetamol, ibuprofen, aspirin) & psychological traits (e.g., depression). Widespread pain affected a range of traits such as an increased risk of surgical complications, analgesic use and disability parking permit use. ECG: electrocardiogram.



Figure 8: Causal architecture plots presenting the relationships of various traits with (**A**) chronic back pain, (**B**) neck/shoulder pain and (**C**) hip pain. Each dot represents a genetic correlation (*rG*). The colour of a dot indicates whether the genetic correlation between them is positive (red) or negative (blue). The x-axis denotes the genetic causal proportion (GCP) estimate and the y-axis denotes the GCP absolute Z-score (i.e., statistical significance). The red dashed line shows the threshold for statistical significance (5% false discovery rate). Traits that have a genetic causal effect on chronic pain are on the left side of the plot (with respect to 0 on the x-axis, GCP < -0.6; black text), while traits causally affected by chronic pain are on the right side (GCP > 0.6; green text). Selected traits are labelled for illustrative purposes — spanning clinical, biological, psychological & socioeconomic measures. Full details of all significant genetic causal relationships are provided in Supplementary Tables S2, S3 & S4. Causal architecture plots for the other regional chronic pain types are presented in Supplementary Figures S1 & S2.





Supplementary Tables

Supplementary Table S1: Distribution of chronic pain across body sites, sex and prevalence in the sample.

Supplementary Table S2: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for traits with significant causal relationships with chronic back pain.

Supplementary Table S3: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for traits with significant causal relationships with chronic neck/shoulder pain.

Supplementary Table S4: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for traits with significant causal relationships with chronic hip pain.

Supplementary Table S5: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for traits with significant causal relationships with chronic knee pain.

Supplementary Table S6: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for traits with significant causal relationships with chronic abdominal pain.

Supplementary Table S7: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for traits with significant causal relationships with chronic facial pain.

Supplementary Table S8: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for traits with significant causal relationships with chronic headaches.

Supplementary Table S9: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for traits with significant causal relationships with chronic widespread pain.

Supplementary Table S10: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for 1,492 traits with chronic back pain.

Supplementary Table S11: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for 1,492 traits with chronic neck/shoulder pain.

Supplementary Table S12: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for 1,492 traits with chronic hip pain.

Supplementary Table S13: Genetic correlation (rG) and genetic causal proportion (GCP) results for 1,492 traits with chronic knee pain.

Supplementary Table S14: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for 1,492 traits with chronic abdominal pain.

Supplementary Table S15: Genetic correlation (rG) and genetic causal proportion (GCP) results for 1,492 traits with chronic facial pain.

Supplementary Table S16: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for 1,492 traits with chronic headache.

Supplementary Table S17: Genetic correlation (*rG*) and genetic causal proportion (GCP) results for 1,492 traits with chronic widespread pain.

Supplementary Table S18: Traits demonstrating contrary directions of causal relationships between chronic pain types.

Supplementary Table S19: Genetic correlation (*rG*) results between chronic pain types.

Supplementary Figures

Supplementary Figure S1: Causal architecture plots presenting the relationships of various traits with (**A**) chronic knee pain, (**B**) widespread pain and (**C**) headaches. Each dot is a data point representing a genetic correlation (*rG*). The colour of a dot indicates whether the genetic correlation between them is positive (red) or negative (blue). The x-axis denotes the genetic causal proportion (GCP) estimate and the y-axis denotes the GCP absolute Z-score (i.e., statistical significance). The red dashed line shows the threshold for statistical significance (5% false discovery rate). Traits that have a genetic causal effect on chronic pain are on the left side of the plot (with respect to 0 on the x-axis; GCP < -0.6, black text), while traits causally affected by chronic pain are on the right side (GCP > 0.6, green text). Selected traits are labelled for illustrative purposes — spanning clinical, biological, psychological & socioeconomic measures. Full details of all significant genetic causal relationships are provided in Supplementary Tables S5, S8 & S9.

Supplementary Figure S2: Causal architecture plots presenting the relationships of various traits with (**A**) chronic abdominal pain and (**B**) facial pain. Each dot is a data point representing a genetic correlation (*rG*). The colour of a dot indicates whether the genetic correlation between them is positive (red) or negative (blue). The x-axis denotes the genetic causal proportion (GCP) estimate and the y-axis denotes the GCP absolute Z-score (i.e., statistical significance). The red dashed line shows the threshold for statistical significance (5% false discovery rate). Traits that have a genetic causal effect on chronic pain are on the left side of the plot (with respect to 0 on the x-axis; GCP < -0.6, black

text), while traits causally affected by chronic pain are on the right side (GCP > 0.6, green text). Selected traits are labelled for illustrative purposes. Full details of all significant genetic causal relationships are provided in Supplementary Tables S6 & S7.